Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer

BACKGROUND: Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate‐resistant disease stage when ADT start becoming less effective. Abiraterone is an ag...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cochrane Database Syst Rev
Hauptverfasser: Sathianathen, Niranjan J, Oestreich, Makinna C, Brown, Sarah Jane, Gupta, Shilpa, Konety, Badrinath R, Dahm, Philipp, Kunath, Frank
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Ltd 2020
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092456/
https://ncbi.nlm.nih.gov/pubmed/33314020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013245.pub2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge